-
Mashup Score: 2
Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 15Cancer statistics, 2025 - 2 hour(s) ago
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes u…
Categories: General Medicine News, Oncologists1Tweet-
🚨 The 2025 @AmericanCancer Cancer Statistics report is here! While cancer deaths dropped 34% since 1991 (4.5M lives saved), rising incidence in women, health disparities, and challenges in pancreatic cancer require urgent attention. Explore the stats: https://t.co/y5QdA0yk85 https://t.co/Ux6RIuyLTQ
-
-
Mashup Score: 0
Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle cell lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
🚨 BREAKING NEWS 🚨The #FDA has approved: Acalabrutinib + BR for adult patients with previously untreated #MCL ineligible for autologous HSCT. https://t.co/mRKwaQbG5f Sotorasib + panitumumab in previously treated #CRC harboring a KRAS G12C mutation. https://t.co/NqVrhQ1pMU
-
-
Mashup Score: 8A Pioneering Journey in Radiation Oncology Inspired by Multidisciplinary Collaboration - 2 hour(s) ago
Fueled by wanting to carry on his father’s legacy, Ralph R. Weichselbaum, MD, created his own mark on radiation therapy in oncologic care.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Read More About a Pioneering Journey in Radiation #Oncology Inspired by Multidisciplinary Collaboration @rweichselbaum @UCCancerCenter @UChicagoMed https://t.co/lmz78tuBo3
-
-
Mashup Score: 4
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.“Combination therapy with teclistamab plus talquetamab showed encouraging antitumor activity in a majority of patients with relapsed or refractory multiple myeloma,” Yael C. Cohen, MD, head of the myeloma
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma. Nearly two-thirds of patients in the study developed grade 3 or grade 4 infections. #Talvey #Tecvayli https://t.co/qfQWg5Sy5B
-
-
Mashup Score: 2Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10 - 3 hour(s) ago
Lee et al. show that neutrophil extracellular traps (NETs) establish the pre-metastatic niche in the omentum by recruiting innate-like B cells and eliciting IL-10 production in these cells through inactivating SHP-1 and generating reactive oxygen species, thereby expanding Tregs. These findings underscore the potential of inhibiting NETs for metastasis prevention.
Source: www.cell.comCategories: General Medicine News, Oncologists1Tweet-
Online Now: Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10 https://t.co/uE1oizO0ak https://t.co/PT3pOUXP0m
-
-
Mashup Score: 0
Biospecimen sharing policies and request forms from NCI-funded population-based studies; potential sources of biospecimens from NCI- and NIH-funded projects.
Source: epi.grants.cancer.govCategories: General Medicine News, Oncologists1Tweet-
Did you know that NCI has biospecimen resources for scientists? Check out our resources, including information on best practices, for researchers seeking specimens and for those looking to share samples. https://t.co/cnS8R2qs2B #CancerResearch https://t.co/wPmHylOSpW
-
-
Mashup Score: 1FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Treated MCL - 4 hour(s) ago
The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
BREAKING🚨: @US_FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Treated MCL #lymsm #oncology https://t.co/42h91X1Xnk https://t.co/aRo732Plcm
-
-
Mashup Score: 0UpToDate® : Oncology Times - 4 hour(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Oncologists1Tweet-
Read this month's UpToDate® to learn "What's New in Oncology?" From treatments for advanced hormone receptor (HR)-positive/HER2-negative breast cancer to therapy for esophageal squamous cell carcinoma, explore recent groundbreaking discoveries. https://t.co/r2E32i34ZH https://t.co/yVQl6lbERP
-
-
Mashup Score: 7FDA approves sotorasib with panitumumab for colorectal cancer - 4 hour(s) ago
On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
Source: www.fda.govCategories: General Medicine News, Oncologists1Tweet-
FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer https://t.co/Ile5FhDjjX #OCENewsBurst
-
Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis @ASH_hematology @TischCancer @IcahnMountSinai #myelofibrosis https://t.co/umIIqIqlsj